Agios Pharmaceuticals Inc (NASDAQ:AGIO) gets upgraded to Outperform by Leerink Swann

Analyst Ratings For Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Story continues below

Today, Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock received an upgrade by Leerink Swann from Market Perform to Outperform.

There are 9 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Agios Pharmaceuticals Inc (NASDAQ:AGIO) is Buy with a consensus target price of $97.00 per share, a potential 68.93% upside.

Some recent analyst ratings include

  • 2/15/2019-Agios Pharmaceuticals Inc (NASDAQ:AGIO) gets upgraded to Outperform by Leerink Swann
  • 11/16/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Hold rating reiterated by Oppenheimer
  • 11/2/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Buy rating reiterated by Cowen
  • 9/17/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) has coverage initiated with a Neutral rating
  • 9/5/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Buy rating reiterated by Canaccord Genuity with a $90.00 price target
  • 8/2/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Buy rating reiterated by Needham & Company LLC
  • On 11/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $69.69 per share and the total transaction amounting to $209,070.00.
  • On 10/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $69.79 per share and the total transaction amounting to $209,370.00.
  • On 9/11/2018 John Maraganore, Director, sold 13,555 with an average share price of $72.75 per share and the total transaction amounting to $986,126.25.
  • On 9/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $83.07 per share and the total transaction amounting to $249,210.00.
  • On 8/30/2018 Christopher Bowden, Insider, sold 1,700 with an average share price of $80.03 per share and the total transaction amounting to $136,051.00.
  • On 8/24/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $74.92 per share and the total transaction amounting to $153,586.00.
  • On 8/6/2018 Scott Biller, Insider, sold 3,000 with an average share price of $80.11 per share and the total transaction amounting to $240,330.00.

About Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Recent Trading Activity for Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Shares of Agios Pharmaceuticals Inc closed the previous trading session at 57.42 up +3.39 6.27% with 52.8 shares trading hands.

An ad to help with our costs